By using a large-scale RNA interference (RNAi) screen to identify genes involved in imatinib responsiveness, Ma et al. discovered an increase activity in RAF/MEK/ERK signaling pathway responsible for BCR-ABL-independent imatinib resistance through CML-LSCs (24). Here, MAP2K7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.